Researchers Seek Out Local Foundations When NIH Rejects Their Grant Proposals

For countless scientists, it's a vicious cycle. They need funds to turn their exploratory research into more viable projects, yet the National Institutes of Health tends to reject grant applications for investigations that are still in the early stages. So what's a researcher to do? The answer may be to turn away from the large, national agencies and toward small, local ones, a prime example of which is the Bryn Mawr, Pa.-based W.W. Smith Charitable Trust. George Preti, organic chemist and sen

Written byBruce Silver
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

For countless scientists, it's a vicious cycle. They need funds to turn their exploratory research into more viable projects, yet the National Institutes of Health tends to reject grant applications for investigations that are still in the early stages. So what's a researcher to do? The answer may be to turn away from the large, national agencies and toward small, local ones, a prime example of which is the Bryn Mawr, Pa.-based W.W. Smith Charitable Trust.

George Preti, organic chemist and senior researcher at the Monell Chemical Senses Center in Philadelphia, was faced with this problem in 1987, when NIH declined to fund his search for a new technique for the early detection of cancer. Like many scientists seeking support in the early stages of research, he did not have sufficient data to qualify for an NIH grant. To get the money to broaden his studies and generate the kind ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies